0.00%
-1.15%
24.10%
27.78%
67.48%
-10.39%
74.60%
AI Spotlight on PROB
Company Description
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies.The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health.It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks.
The company sells its products approximately in 40 countries worldwide.It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women.The company was incorporated in 1991 and is headquartered in Lund, Sweden.
Probi AB (publ) is a subsidiary of Symrise AG.
Market Data
| Last Price | 345 |
| Change Percentage | 0.00% |
| Open | 345 |
| Previous Close | 345 |
| Market Cap ( Millions) | 3931 |
| Volume | 155 |
| Year High | 351 |
| Year Low | 197 |
| M A 50 | 348.12 |
| M A 200 | 279.38 |
Financial Ratios
| FCF Yield | 2.07% |
| Dividend Yield | 0.37% |
| ROE | 0.78% |
| Debt / Equity | 5.94% |
| Net Debt / EBIDTA | -235.68% |
| Price To Book | 2.92 |
| Price Earnings Ratio | 366.4 |
| Price To FCF | 48.24 |
| Price To sales | 6.33 |
| EV / EBITDA | 32.69 |
News
- Jan -21 - Exploring Three High Growth Tech Stocks with Promising Potential
- Dec -23 - Exploring High Growth Tech Stocks This December 2024
- Nov -22 - Exploring High Growth Tech Stocks Including Avalon Technologies And Two Others
- Oct -24 - Exploring High Growth Tech Stocks in Sweden October 2024
- Oct -23 - Probi AB (OSTO:PROB) Q3 2024 Earnings Call Highlights: Navigating Growth Challenges with ...
- Sep -25 - High Growth Tech Stocks in Sweden to Watch This September 2024
- Aug -27 - High Growth Tech Stocks in Sweden To Watch This August 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Probiotics
Expected Growth : 6 %
What the company do ?
Probiotics from Probi AB (publ) are live microorganisms that, when administered in adequate amounts, confer a health benefit, supporting gut health and immune system function.
Why we expect these perspectives ?
Probiotics from Probi AB (publ) growth driven by increasing consumer awareness of gut health, rising demand for natural and preventative healthcare solutions, expansion into new markets, and strategic partnerships. Additionally, growing evidence of probiotics' benefits in immune system support and digestive health contributes to the segment's 6% growth.
Segment n°2 -> Royalties
Expected Growth : 6 %
What the company do ?
Royalties from Probi AB (publ) refer to the payment made to the company for the use of its intellectual property, such as patents, trademarks, or copyrights.
Why we expect these perspectives ?
Probi AB's 6% royalty growth is driven by increasing demand for probiotics in the food and pharma industries, expansion into new markets, and a growing portfolio of patented strains. Additionally, rising consumer awareness of gut health and wellness, coupled with strategic partnerships and collaborations, contribute to the company's royalty growth.
Probi Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Probiotics | Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Probi AB develops and manufactures probiotics for human health and animal nutrition. |
| Probi FerroSorb | Probi FerroSorb is a probiotic strain that helps increase iron absorption in the body. |
| Probi Digestis | Probi Digestis is a probiotic strain that helps maintain a healthy gut microbiome and supports digestion. |
| Probi Defendum | Probi Defendum is a probiotic strain that helps support the immune system and reduce inflammation. |
| Probi FerroSorb+ | Probi FerroSorb+ is a probiotic strain that helps increase iron absorption and supports healthy red blood cell production. |
| Probiotics for Animal Nutrition | Probiotics for animal nutrition are designed to support the health and well-being of animals, improving their digestive health and immune system. |
Probi AB (publ)'s Porter Forces
Threat Of Substitutes
Probi AB (publ) operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the growing demand for probiotics and the increasing competition in the market.
Bargaining Power Of Customers
Probi AB (publ) has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Probi AB (publ) relies on a few key suppliers for its raw materials, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate prices mitigate this risk.
Threat Of New Entrants
The probiotics market has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized manufacturing facilities. This makes it difficult for new entrants to enter the market.
Intensity Of Rivalry
The probiotics market is highly competitive, with several established players competing for market share. Probi AB (publ) faces intense competition from companies such as Chr. Hansen, DuPont, and Lallemand.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.78% |
| Debt Cost | 3.95% |
| Equity Weight | 96.22% |
| Equity Cost | 6.68% |
| WACC | 6.58% |
| Leverage | 3.93% |
Probi AB (publ) : Quality Control
Probi AB (publ) passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHN.MI | Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The … |
| INCR | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis … |
| BMK.L | Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe … |
| APH.L | Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and … |
| KMDA | Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharmanutra
A-Score
1-Year Total Return ->
🥈
Alliance Pharma
A-Score
1-Year Total Return ->
🥉
Kamada
A-Score
1-Year Total Return ->
4
Benchmark
A-Score
1-Year Total Return ->
5
Probi
A-Score
1-Year Total Return ->
6
